Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35145
Title: Clinical utility of maternal TORCH screening in fetal growth restriction: A retrospective two-centre study.
Austin Authors: Wade, Christine A;Atkinson, Naomi;Holmes, Natasha E ;Hui, Lisa 
Affiliation: Infectious Diseases
Department of Obstetrics and Gynaecology, Northern Health, Melbourne, Victoria, Australia.
Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Department of Perinatal Medicine, Mercy Hospital for Women, Melbourne, Victoria, Australia.
Department of Obstetrics and Gynaecology, Northern Health, Melbourne, Victoria, Australia.;Department of Perinatal Medicine, Mercy Hospital for Women, Melbourne, Victoria, Australia.;Department of Obstetrics, Gynaecology and Newborn Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Department of Infectious Diseases, Northern Health, Melbourne, Victoria, Australia.
Issue Date: Aug-2024
Date: 2024
Publication information: The Australian & New Zealand Journal of Obstetrics & Gynaecology 2024-08; 64(4)
Abstract: The aim of this study was to evaluate the indications for maternal TORCH (Toxoplasma gondii, rubella, cytomegalovirus (CMV), and herpes simplex virus (HSV)) serology, with a focus on the yield in isolated fetal growth restriction (FGR). A retrospective review of antenatal TORCH testing between January 2014 and December 2018 was carried out at two hospitals in Melbourne, Australia. TORCH testing ordered for pregnancy losses and stillbirth was excluded. Medical records of 718 pregnancies were reviewed, representing 760 fetuses. Isolated FGR was the indication for TORCH screening in 71.2% of pregnancies. Screens ordered for isolated FGR were positive in 7.4% (95% CI 5.5-10.0%). There were 49 positive maternal immunoglobulin M (CMV = 34, Toxoplasma = 15). Two acute maternal infections during pregnancy were diagnosed (CMV = 1, Toxoplasma = 1), with both screens ordered to assess symptomatic maternal illness. There was one neonatal CMV infection, born to a woman with symptomatic primary CMV. No maternal or neonatal rubella or HSV infections were identified. We found a diagnostic yield of TORCH screening for isolated FGR of 0.0% (95% CI 0.00-0.8%). An estimated AUD$64 269.75 was expended on maternal TORCH screens in this study. Maternal TORCH testing for isolated FGR is of no diagnostic yield and should be abandoned.
URI: https://ahro.austin.org.au/austinjspui/handle/1/35145
DOI: 10.1111/ajo.13802
ORCID: 0009-0006-0413-0218
0000-0002-9720-3562
Journal: The Australian & New Zealand Journal of Obstetrics & Gynaecology
PubMed URL: 38380539
ISSN: 1479-828X
Type: Journal Article
Subjects: TORCH
congenital infection
cytomegalovirus
fetal growth restriction
toxoplasma
Appears in Collections:Journal articles

Show full item record

Page view(s)

48
checked on Oct 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.